SecBot SecBot
PRESS-RELEASE ·Filed Mar 5, 2026

LXRX

Lexicon Pharmaceuticals, Inc.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

While headline financials show improved efficiency and cash flow, declining product revenue and reliance on non-recurring licensing income suggest limited commercial traction for INPEFA. Pipeline catalysts in 2026–2027 (NDA resubmission, SONATA enrollment, pilavapadin Phase 3 start) are key value drivers. Monitor partnership progress on pilavapadin and NDA acceptance for ZYNQUISTA.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.64
T+0 close · Mar 5, 2026 · via day close
Latest settled
+26.22%
T+60 · $2.07
Vs SPY
+14.92%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $1.64entry
  2. T+1 · 9mo ago +4.27%α +5.58% · $1.71
  3. T+5 · 8mo ago +4.88%α +7.12% · $1.72
  4. T+20 · 8mo ago −3.05%α +0.74% · $1.59
  5. T+60 · 6mo ago +26.22%α +14.92% · $2.07
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lexicon Pharmaceuticals reported Q4 and full-year 2025 financial results with significantly reduced net loss and lower operating expenses, driven by strategic repositioning. The company highlighted key pipeline progress, including sotagliflozin NDA resubmission plans for T1D and mid-2026 enrollment completion expected for the SONATA-HCM Phase 3 study. A $106.7M capital raise and milestone payment in February 2026 strengthened its cash position to over $220M.

Key Financial Metrics

Revenue
$5.5M
-79.3% YoY
EPS
$-0.04
Deal Value
$106.7M

Key Facts

  • Q4 2025 revenue was $5.5M (vs. $26.6M in Q4 2024), driven by $4.3M in licensing revenue and $1.1M in INPEFA net sales.
  • Full-year 2025 revenue was $49.8M (vs. $31.1M in 2024), primarily due to $45M upfront licensing payment from Novo Nordisk.
  • Net loss narrowed to $15.5M in Q4 2025 (vs. $33.8M in Q4 2024) and $50.3M for full-year 2025 (vs. $200.4M in 2024).
  • R&D and SG&A expenses declined sharply year-over-year due to reduced trial costs and strategic repositioning.
  • Cash, investments, and restricted cash totaled $125.2M as of Dec 31, 2025; additional $106.7M raised in Feb 2026.
  • FDA confirmed pilavapadin’s Phase 3 readiness after End-of-Phase 2 meeting; partnership discussions ongoing.
  • SONATA-HCM Phase 3 trial is over 50% enrolled with completion expected mid-2026 and topline data in Q1 2027.

Financial Impact

Reduced annual net loss by $150M YoY; raised $106.7M in early 2026, extending cash runway significantly.

net_losscash_positionrevenuer_and_d_expensesga_expense

Risk Factors

  • Dependence on non-recurring licensing revenue masks weak product sales growth.
  • INPEFA commercial performance remains muted with only $1.1M in Q4 sales.
  • Pipeline setbacks could jeopardize long-term value, especially if ZYNQUISTA NDA is not accepted or SONATA fails.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3249981

Track record

16 reports on LXRX

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +27.52% at T+20 after the Sep 22, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
  2. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  3. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $2.18 to $2.06 Now $1.75 +19.72% ▲ +5.50% +4.78% vs SPY
  5. Aug 6, 202614w ago 8-K Neutral 5/10 No price data
  6. Aug 6, 202614w ago Press Release Neutral 5/10 Entry $2.36 to $2.47 Now $1.75 −25.85% ▲ +4.66% +4.05% vs SPY
  7. Jun 12, 202622w ago Institutional Cluster Bearish 5/10 Entry $1.92 to $1.96 Now $1.75 +8.85% ▼ −2.08% −0.32% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.89 to $1.92 Now $1.75 −7.41% ▲ +1.59% +1.05% vs SPY
  9. May 6, 202627w ago 8-K Neutral 4/10 Entry $1.68 to $1.68 Now $1.75 +4.17% · 0.00% −0.83% vs SPY
  10. Apr 30, 202628w ago 8-K Bearish 6/10 Entry $1.63 to $1.60 Now $1.75 −7.36% ▲ +1.84% +1.50% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026